Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733765) titled 'A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata' on July 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Pfizer
Condition:
Alopecia Areata
Intervention:
Drug: Ritlecitinib 100 mg
Drug: Ritlecitinib 50 mg
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: July 31, 2026
Target Sampl...